# Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

> **NCT07750067** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 37 (estimated)

## Conditions studied

- Melanoma Metastatic
- NRAS Mutation

## Interventions

- **DRUG:** Tunlametinib
- **DRUG:** Pucotenlimab
- **DRUG:** Hydroxychloroquine (HC)

## Key facts

- **NCT ID:** NCT07750067
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-07-28
- **Final completion:** 2030-07-28
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750067, "Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*